Best Diversified Pharmaceuticals Companies in Israel
The 33 best Diversified Pharmaceuticals companies in Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Pharma Two B.
- The Business Research Company
- Data Bridge Market Research
Ranked: Best Diversified Pharmaceuticals companies in Israel
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Pharma Two B Pharma Two B is a late-stage pharmaceutical company developing innovative combination products of previously… | $38M | 116 mo ago | 12 | — | — | 60 patents Oral and sustained-release pharmaceutical formulations for Parkinson's disease treatment | — |
| 2 | Can-Fite Developer of small molecules for autoimmune-inflammatory and cancer diseases | $26M | 58 mo ago | 8 | Pnina Fishman Co-Founder & CEO | — | 225 patents A3 adenosine receptor agonist therapeutics for inflammatory and cancer diseases | — |
| 3 | BioLineRx Clinical stage biopharmaceutical development company | $23M | 142 mo ago | 49 | Avi Molcho Co-Founder | 3 signals ▼84% Earnings | 206 patents Patents concentrated in health & consumer products | — |
| 4 | Mileutis Developing peptide-based antibiotics for human and animal health | $20M | 72 mo ago | 38 | David Javier Iscovich CEO | — | 78 patents Improving milk quality and treating skin/mammary disorders using casein hydrolysate formulations. | — |
| 5 | Kadimastem Stem Cell for the treatment of diabetes mellitus and amyotrophic lateral sclerosis (ALS) | $18M | 60 mo ago | 31 | — | — | 46 patents Patents concentrated in chemistry & materials | — |
| 6 | Cytora Developer of stem cell technology for chronic wounds and autoimmune disorders | $17M | 64 mo ago | 8 | — | — | 6 patents Stem cell cryopreservation formulations and neurotherapeutic treatment methods for neurological diseases | — |
| 7 | Proteologics Ubiquitin system-based drugs for cancer & infectious diseases | $17M | 300 mo ago | — | — | — | 46 patents Small-molecule inhibitors targeting pyrimidine/quinazolinone kinases and ubiquitin pathways for drug discovery. | — |
| 8 | XTL Biopharmaceuticals Protein therapeutics for inflammatory diseases such as systemic lupus erythematosus and multiple myeloma. | $11M | 26 mo ago | 4 | — | 12 signals ▲71% Announcements · Leadership · M&A | 21 patents Peptide therapeutics for lupus and antiviral small‑molecule/antibody formulations | — |
| 9 | Dynamix Pharmaceuticals Developing small molecule kinase II inhibitors for cancer and autoimmune diseases | $10M | 212 mo ago | 11 | Oren Becker Founder | — | 9 patents Small-molecule kinase modulators, especially sulfonamide PKM2 inhibitors and pyrazoline anticancer agents. | — |
| 10 | Entera Bio Developing parathyroid hormone for hypoparathyroidism, osteoporosis and bone healing | $10M | 34 mo ago | 21 | — | — | 114 patents Oral peptide drug delivery using acid‑neutralizing polymer formulations | — |
| 11 | BioMAS Tellurium-based integrin inhibitors for range of indications | $2M | 151 mo ago | 34 | Benjamin Sredni Co-Founder | — | 85 patents Tellurium-based compounds for anti‑angiogenic, anti‑viral, and dermatological therapies | — |
| 12 | Optimata Develops technologies for predicting improved patient therapy and manufactures medical devices for oncology | $2M | 106 mo ago | 11 | Zvia Agur Founder & CSO | — | 35 patents Patents concentrated in computing, sensing & instrumentation | — |
| 13 | GeneGrafts Cell-therapy for neurological disorders and cardiac arrhythmias. | $800K | 274 mo ago | 1 | Yair Feld Founder & CEO | — | 23 patents Gene therapy targeting ion channels to modulate electrophysiology of excitable tissues | — |
| 14 | Cell Source Cell therapy treatments for transplantation, cancer treatment and reversal of vital organ disease | $398K | 9 mo ago | 1 | — | — | — | — |
Top 12 Diversified Pharmaceuticals companies in Israel
#1
Public · Tel Aviv, Tel Aviv · founded 2011 · 1 employees$397.5Kraised▾
Cell Source is a biotechnology company developing cell therapy treatments based on the management of immune tolerance. Its flagship technology is the Veto Cell platform. Veto cells are white blood cells taken from either the patient or a healthy third-party donor. They are then processed using a mix of off-the-shelf cytokines that change their characteristics and activate their inherent “attacker blocking” capability. The company also has Megadose, a treatment involving a large number of stem cells to facilitate bone marrow transplants in cases with partially-matched donors. It is working on Megadose-drug combination platforms. It currently has 2 Megadose + drug combinations (PoC and pre-clinical stages) and 2 pre-clinical Veto cell programs for anti-rejection and anti-lymphoma.
- Jan 2026Post IPO$1.5M
- Oct 2023Post IPO$3.9M
- Oct 2019Post IPO$8.9M
- Nov 2015Seed$252.5K
#2
Public · Ra anana, Center District · founded 1993 · 4 employees$10.6Mraised▾
XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has two product candidates in clinical development: hCDR1 peptide for the treatment of Systemic Lupus Erythematosus (SLE) (Phase 2); Recombinant Erythropoietin (rHuEPO) for the prolongation of multiple myeloma (MM) advanced-stage patients’ survival (Phase 1).
#3
Public · Jerusalem, Jerusalem District · founded 2010 · 21 employees$9.5Mraised▾
Entera Bio is a clinical stage company focussed on the development of drugs based on its drug delivery platform which can be used for the oral delivery of large molecule protein APIs. It claims that its technology combines drug delivery entities to increase its half-life and bioavailability and thereby protects the large molecules and peptides in the GI tract. Its lead candidate PTH- 1-34 (Teriparatide) is an oral formulation of the active element of the parathyroid hormone which is being developed for hypoparathyroidism, osteoporosis and bone healing.
- Dec 2023Post IPO$6.6M
- Dec 2019Post IPO$14.3M
- Oct 2017Series A$2M
- Jul 2016Series A$7.5M
#4
Public · Ness Ziona, Center District · founded 2009 · 31 employees$18.2Mraised▾
Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The company’s proprietary technologies and know-how enable the differentiation of stem cells into insulin-secreting as a range of neural cells (Oligodendrocytes, Astrocytes). Based on its differentiation technologies, the company is advancing two therapeutic programs focused on diabetes mellitus and ALS, where stem cells are differentiated into beta cells (for the diabetes program) and astrocytes (for the ALS program) with the goal of implanting them into patients, and affecting diseases progression. Also collaborating for optimizing drug development through pluripotent stem cell-derived cells.
- Oct 2021Post IPO$5M
- Oct 2018Post IPO$5.2M
- Mar 2018Grant (prize money)$319.4K
- Dec 2016Post IPO$7M
#5
Public · Petah Tikva, Central District · founded 1994 · 8 employees$25.5Mraised▾
Developer of small molecules for autoimmune-inflammatory and cancer diseases
#6
Series B · Israel · founded 2018 · 8 employees$17Mraised▾
Developer of stem cell technology for chronic wounds and autoimmune disorders. The company focuses on creating off-the-shelf products using human oral mucosa stem cells. These products aim to address neurodegenerative diseases and other conditions with unmet medical needs. The technology offers cell replacement and paracrine trophic effects.
- 2021Grant (prize money)$5M
- Series B$12M
#7
Series C · Rehovot, Central District · founded 2007 · 12 employees$38Mraised▾
Pharma Two B is a late-stage pharmaceutical company focused on developing innovative combination products of previously approved drugs to improve patient outcomes. The company is pioneering a novel approach to treating Parkinson's disease, with its lead product, P2B001, demonstrating promising results in clinical trials. With a strong pipeline of products in development, Pharma Two B is poised to make a significant impact in the pharmaceutical industry.
#8
Series A · Gan Yavne, Center District · founded 2005 · 38 employees$20Mraised▾
Mileutis is a biopharmaceutical company focused on the discovery and development of peptide-based antimicrobial therapies for animal and human health. Its human drug pipeline has 3 candidates namely MLT-4, MLT-1002 and MLT-1003 in the development stage for breast inflammation & programmable cell death. It also has 5 animal drug candidates with four of them available for licensing.
#9
Public · Modi in Maccabim Re ut, Center District · founded 2003 · 49 employees$23Mraised▾
BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. It in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRx's pipeline currently consists of six clinical stage therapeutic candidates which could be used in case of acute myeloid leukemia (AML), celiac disease, non-surgical removal of skin lesions, inflammatory bowel disease, interferon-free treatment for Hepatitis C, a medical device developed for the prevention of cardiac remodeling in acute myocardial infarction patients. It also has a multi-year strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates.
#10
Acquired · Rehovot, Central District · founded 1999$17Mraised▾
Ubiquitin system-based drugs for cancer & infectious diseases
#11
Series A · Rehovot, Central District · founded 2009 · 11 employees$10Mraised▾
Developer of novel, targeted, small-molecule drugs created to treat cancer and autoimmune disorders. The company's small-molecule drugs intervene with the metabolism of cancer cells and selectively target specific cellular signaling pathways, also known as Type II kinase inhibitors, enabling physicians to treat urgent and unmet medical needs in cancer and autoimmune disorders.
#12
Deadpooled · Jerusalem, Jerusalem District · founded 2000 · 34 employees$2Mraised▾
Tellurium-based integrin inhibitors for range of indications
Funding & investor landscape
Notable founders
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.